Erlotinib Terminated Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02556593IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
NCT00281021Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer